Pretargeting of internalizing trastuzumab and cetuximab with a 18F-tetrazine tracer in xenograft models

Show full item record



Permalink

http://hdl.handle.net/10138/230094

Citation

Keinänen , O , Fung , K E , Pourat , J , Jallinoja , V , Vivier , D , Pillarsetty , N K , Airaksinen , A , Lewis , J S , Zeglis , B M & Sarparanta , M 2017 , ' Pretargeting of internalizing trastuzumab and cetuximab with a 18 F-tetrazine tracer in xenograft models ' , EJNMMI Research , vol. 2017 , no. 7 , 95 . https://doi.org/10.1186/s13550-017-0344-6

Title: Pretargeting of internalizing trastuzumab and cetuximab with a 18F-tetrazine tracer in xenograft models
Author: Keinänen, Outi; Fung, Kimberly E; Pourat, Jacob; Jallinoja, Vilma; Vivier, Delphine; Pillarsetty, NagaVara Kishore; Airaksinen, Anu; Lewis, Jason S; Zeglis, Brian M; Sarparanta, Mirkka
Contributor: University of Helsinki, Doctoral Programme in Chemistry and Molecular Sciences
University of Helsinki, Department of Chemistry
University of Helsinki, Department of Chemistry
University of Helsinki, Tracers in Molecular Imaging (TRIM)
Date: 2017-12-02
Language: eng
Number of pages: 12
Belongs to series: EJNMMI Research
ISSN: 2191-219X
URI: http://hdl.handle.net/10138/230094
Abstract: Pretargeting-based approaches are being investigated for radioimmunoimaging and therapy applications to reduce the effective radiation burden to the patient. To date, only a few studies have used short-lived radioisotopes for pretargeting of antibodies, and such examples with internalizing antibodies are even rarer. Herein, we have investigated pretargeting methodology using inverse electron-demand Diels-Alder (IEDDA) for tracing two clinically relevant, internalizing monoclonal antibodies, cetuximab and trastuzumab. Bioorthogonal reaction between tetrazine and trans-cyclooctene (TCO) was used for tracing cetuximab and trastuzumab in vivo with a fluorine-18 (t (A 1/2) = 109.8 min) labelled tracer. TCO-cetuximab or TCO-trastuzumab was administered 24, 48, or 72 h prior to the injection of tracer to A431 or BT-474 tumour-bearing mice, respectively. With cetuximab, the highest tumour-to-blood ratios were achieved when the lag time between antibody and tracer injections was 72 h. With trastuzumab, no difference was observed between different lag times. For both antibodies, the tumour could be clearly visualized in the PET images with the highest tumour uptake of 3.7 +/- 0.1%ID/g for cetuximab and 1.5 +/- 0.1%ID/g for trastuzumab as quantified by ex vivo biodistribution. In vivo IEDDA reaction was observed in the blood for both antibodies, but with trastuzumab, this was to a much lower degree than with cetuximab. We could successfully visualize the tumours by using cetuximab and trastuzumab in pretargeted PET imaging despite the challenging circumstances where the antibody is internalized and there is still some unbound antibody circulating in the blood flow. This clearly demonstrates the potential of a pretargeted approach for targeting internalizing antigens and warrants development of pharmacokinetic optimization of the biorthogonal reactants to this end.
Subject: 116 Chemical sciences
positron emission tomography (PET)
radiolabeling
Bioorthogonal chemistry
pretargeting
monoclonal antibody
internalization
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
s13550_017_0344_6.pdf 1.848Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record